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Abstract
Background: Thyroid nodules represent a common problem brought to medical attention. Four
to seven percent of the United States adult population (10–18 million people) has a palpable thyroid
nodule, however the majority (>95%) of thyroid nodules are benign. While, fine needle aspiration
remains the most cost effective and accurate diagnostic tool for thyroid nodules in current practice,
over 20% of patients undergoing FNA of a thyroid nodule have indeterminate cytology (follicular
neoplasm) with associated malignancy risk prevalence of 20–30%. These patients require thyroid
lobectomy/isthmusectomy purely for the purpose of attaining a definitive diagnosis. Given that the
majority (70–80%) of these patients have benign surgical pathology, thyroidectomy in these patients
is conducted principally with diagnostic intent. Clinical models predictive of malignancy risk are
needed to support treatment decisions in patients with thyroid nodules in order to reduce
morbidity associated with unnecessary diagnostic surgery.
Methods: Data were analyzed from a completed prospective cohort trial conducted over a 4-year
period involving 216 patients with thyroid nodules undergoing ultrasound (US), electrical
impedance scanning (EIS) and fine needle aspiration cytology (FNA) prior to thyroidectomy. A
Bayesian model was designed to predict malignancy in thyroid nodules based on multivariate
dependence relationships between independent covariates. Ten-fold cross-validation was
performed to estimate classifier error wherein the data set was randomized into ten separate and
unique train and test sets consisting of a training set (90% of records) and a test set (10% of
records). A receiver-operating-characteristics (ROC) curve of these predictions and area under
the curve (AUC) were calculated to determine model robustness for predicting malignancy in
thyroid nodules.
Results: Thyroid nodule size, FNA cytology, US and EIS characteristics were highly predictive of
malignancy. Cross validation of the model created with Bayesian Network Analysis effectively
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predicted malignancy [AUC = 0.88 (95%CI: 0.82–0.94)] in thyroid nodules. The positive and
negative predictive values of the model are 83% (95%CI: 76%–91%) and 79% (95%CI: 72%–86%),
respectively.
Conclusion:  An integrated predictive decision model using Bayesian inference incorporating
readily obtainable thyroid nodule measures is clinically relevant, as it effectively predicts malignancy
in thyroid nodules. This model warrants further validation testing in prospective clinical trials.
Background
Thyroid nodules represent a common problem brought to
medical attention. Four to seven percent of the United
States adult population (10–18 million people) has a pal-
pable thyroid nodule(s), and up to 50% of American
women older than age 50 have nodules visible by ultra-
sound [1]. The majority (>95%) of thyroid nodules are
benign; however, malignancy risk increases with male
gender, nodule size, rapid growth and associated symp-
toms, extremes of age (< 30 and > 60 years), underlying
autoimmune disease, nodule growth under thyroid hor-
mone suppression, personal or family history of thyroid
malignancy and radiation exposure [2].
Thorough history and physical examination, serum thyro-
tropin (TSH) level, thyroid ultrasound (US) and fine need
aspiration (FNA) comprise the standard evaluation of
patients with thyroid nodules. Patients with thyroid nod-
ules typically undergo both thyroid US and FNA. Nodules
with maximum diameter > 1.0–1.5 cm with solid ele-
ments, or nodules demonstrating suspicious features on
US particularly should undergo FNA [3]. Given the
increased risk of malignancy in so-called thyroid inciden-
talomas detected by 18FDG-PET (14–50%) or sestamibi
scan (22–66%), FNA is indicated under these circum-
stances as well [4,5].
Fine needle aspiration remains the most cost effective and
accurate diagnostic tool for thyroid nodules in current
practice. Although a standard of practice, FNA remains an
imperfect diagnostic test for thyroid nodules, particularly
when one considers the high frequency (>20%) of inde-
terminate cytology. A six tier classification system for FNA
is favored that is associated with increased risk of malig-
nancy across the spectrum of unsatisfactory or non-diag-
nostic FNA (unknown), benign (<1%), follicular lesion
(atypia) of undetermined significance (5–10%), follicular
neoplasm (20–30%), suspicious for malignancy (50–
75%), malignant (100%) [3]. In experienced hands, sen-
sitivity and specificity are very high, 95% and 99%, respec-
tively, but sensitivity and specificity of FNA varies
considerably, as it is highly dependent on the operator as
well as the cytologist's skills [6,7]. In studies where cytol-
ogy was compared to histology or revised by an expert
cytologist, inaccuracy of the initial diagnosis was observed
in up to 61% of the cases [8]. Unfortunately over 20% of
patients undergoing FNA of a thyroid nodule have inde-
terminate cytology (follicular neoplasm) with associated
malignancy risk prevalence of 20–30%, and they require
thyroid lobectomy/isthmusectomy purely for the purpose
of attaining a definitive diagnosis. Given that the majority
(70–80%) of patients with "follicular neoplasm" has
benign surgical pathology, thyroidectomy in these
patients is conducted principally with diagnostic intent
[9].
This emphasizes the need for non-invasive diagnostic
imaging modalities with improved cancer detection accu-
racy coupled with clinically-relevant, treatment-directing
malignancy risk prediction models to assist the clinician
in the interpretation of available diagnostic information
and minimize the frequency of purely diagnostic thyroid
resections. We have previously studied the potential value
of electrical impedance scanning (EIS) of thyroid nodules
in a prospective feasibility trial. The overall diagnostic
accuracy (73%) of EIS in that study was clinically mean-
ingful, as utilization of the technology could result in a
significant reduction (67%) in the number of purely diag-
nostic thyroid resections for cytologically determined fol-
licular neoplasm [10].
Bayesian Belief Networks or Bayesian classification has
gained acceptance as a methodology for characterizing
multi-dimensional or complex data sets pursuant to
developing disease risk prediction models [11,12]. A
Bayesian Belief Network (BBN) is a graphical model that
represents variables and their probabilistic independen-
cies. Clinical observations such as symptoms, imaging
data and lab results may be encoded into a BBN in order
to estimate the probability of a disease or disorder
[13,14].
Advances in machine learning allow users to train these
networks on complex clinical problems using an intuitive
computer program [15]. A BBN encodes the joint proba-
bility distribution of all the variables in the data set by
building a directed acyclic network of conditional proba-
bilities incorporating independent predictor nodes (varia-
bles), each with its own prior probability [11,16].
Conditional independence statements are embedded in
the network structure through the arcs that connect the
network's nodes [15]. These network arcs between nodesBMC Surgery 2009, 9:12 http://www.biomedcentral.com/1471-2482/9/12
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define a hierarchy and structure of information. Bayesian
networks allow clinicians to derive insights about the data
domain because the networks are graphical, hierarchical
representations of how conditionally independent varia-
bles associate to inform a dependent outcome of interest,
such as presence of malignancy. The inferential structure
of the network allows the clinician to collect a priori evi-
dence of independent variables, add this knowledge to the
network and receive a posteriori probability of outcome.
We hypothesized that a Bayesian Belief Network analyti-
cal tool could be constructed using a machine learning
platform applied to this specific patient study population
represented by relevant clinical variables (e.g. patient age,
gender, thyroid nodule size, US and impedance character-
istics, and FNA cytology) in order to develop a model-
derived risk assessment tool, which could support deci-
sion making on the basis of individual patient risk of
malignancy. We further hypothesized that co-dependent
analysis of EIS in the context of standard testing (US,
FNA) would increase the utility of all of these studies
through clinical decision support. The primary focus of
this analysis is to determine the feasibility of a Bayesian
predictive model to assist the clinician in interpreting
diagnostic information.
Methods
We trained a Bayesian classifier on a prospectively
enrolled cohort [(n = 216; 110 with malignant thyroid
nodules (51%)] collected over a four year period (Sept
2002 – Dec 2006) in the context of a previously published
IRB-approved clinical trial including thyroid impedance,
ultrasound imaging, cytological and histopathological
outcome data [10,17]. This was a prospective single arm
observational cohort trial evaluating the diagnostic accu-
racy of pre-operative thyroid EIS in patients scheduled to
undergo thyroidectomy. Fifty percent of patients (n =
109) were undergoing diagnostic thyroidectomy for inde-
terminate FNA cytology. The objective was to train and
validate a classifier that could be used for clinical decision
making.
Thyroid EIS Examination
Thyroid EIS was performed as described previously [10].
Thyroid EIS was conducted prior to thyroid surgery using
the T-Scan 2000ED [TransScan Medical (Mirabel®), Aus-
tin, TX].
Impedance recordings of conductivity and capacitance
were obtained over the entire gland in a predetermined
sequence using a real-time image acquisition technique
over a broad frequency range (frequency range, 50–
20,000 Hz). A gray-scale impedance map provided an
anatomical image corresponding to the area of interest
directed to a palpable or sonographic thyroid nodule.
Homogeneous gray scale impedance maps (uniform con-
ductivity and capacitance) are characteristic of normal or
benign thyroid nodules, which demonstrate similar con-
ductivity and capacitance (or impedance) to normal thy-
roid tissue. A focal disturbance in electrical field
distribution by a malignant tumor due to its increased
conductivity and, or capacitance (or decreased imped-
ance) appears as a focal bright white spot on the gray scale
impedance map. Changes from baseline sternocleidomas-
toid conductivity and capacitance were calculated for the
thyroid nodule(s). A positive EIS examination was previ-
ously defined as a focal bright spot over a thyroid nodule
correlating with increased conductivity (decreased imped-
ance) and/or capacitance >25% baseline sternocleidomas-
toid muscle impedance, absent confounding local artifact
[10,17].
For the purpose of this study two surgical oncologists (AS,
AN) with extensive experience with EIS in general, and the
T-Scan 2000ED in particular, performed critical review of
impedance scans conducted in the previous trial, both
blinded to fine needle aspirate cytology and surgical
pathology results. They determined an EIS level of suspi-
cion (LOS) score on the basis of a focal white spot pres-
ence and increased conductivity and, or capacitance (with
the previously established 25% above baseline impedance
cutoff) associated with the palpable or sonographic thy-
roid abnormality. Thyroid nodule Level of Suspicion was
classified as follows in the blinded review: LOS 1: Defi-
nitely benign; LOS 2: Highly unlikely to be malignant;
LOS 3: Unlikely to be malignant; LOS 4: Likely to be
malignant; and, LOS 5: Highly likely to be malignant.
Thyroid nodules corresponding to a palpable or sono-
graphic abnormality determined to have LOS of 4 or 5
were considered EIS-positive; otherwise they were
regarded EIS-negative.
All study subjects underwent thyroid resection after thy-
roid US, FNA and EIS. Surgical histopathology was corre-
lated with sonographic, cytological and impedance
findings and interpretations.
FNA and surgical specimens were evaluated by experi-
enced board-certified cytologists and thyroid pathologists
who rendered cytological and histopathological diagnosis
without knowledge of EIS level of suspicion for malig-
nancy.
Statistical Analysis Plan Using Bayesian Belief Networks
Study data were collected and assembled into a data set
consisting of 216 subjects, 109 with indeterminate cytol-
ogy results. Biopsy results were classified based on estab-
lished clinical guidelines into either Benign (n = 106) or
Malignant (n = 110) diagnoses and assembled into a mas-
ter data set. The master data set was then randomized intoBMC Surgery 2009, 9:12 http://www.biomedcentral.com/1471-2482/9/12
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ten additional cross-validation sets. Each subject record
was assigned a randomly generated number. These num-
bers were then used to assign the subjects to ten unique
test groups. A unique training set consisting of the remain-
ing 90% of cases was created for each test group.
Data analysis was then conducted using a Bayesian Belief
Network (BBN). The BBN was built by applying a set of
heuristics to generate predictive models with different
conditional independence assumptions. The BBN we con-
structed encoded the joint probability distributions of all
the variables in our clinical data set from our previously
published clinical trial by building a network of condi-
tional probabilities [17]. The BBN is a directed network
incorporating parent-child relationships between nodes.
The network was queried to provide estimates for poste-
rior probabilities given a priori knowledge, and tested for
accuracy using data withheld from the training model.
The Bayesian network in this study was constructed using
FasterAnalytics™, (DecisionQ, Washington, DC).
The network was validated using a train-and-test cross-val-
idation methodology, in this instance ten-fold cross-vali-
dation. Cross-validation is an established technique in
multivariate analysis which allows researchers to estimate
the performance of predictive models when used outside
of the research setting. This analysis calculates predictive
values by classifying the outcome (surgical pathology
diagnosis) for a given instance and comparing this predic-
tion to the known value in an independent test set. The
test set predictions were then used to calculate a receiver-
operating characteristic (ROC) curve and inference matrix
by threshold for each test set by clinical feature of interest.
The curve was calculated by comparing the predicted
value for each feature of interest to the known value in the
test set on a case-specific basis, rank-ordering the resulting
predictions from most likely to least likely and calculating
the curve using the assumption that the most likely cases
would be evaluated first. This curve was then used to cal-
culate area-under-the-curve (AUC), positive and negative
predictive value (PPV and NPV).
Results
Clinical, image-based, cytological and pathological char-
acteristics of the population are demonstrated in Table 1.
Importantly the disproportionately high prevalence of
indeterminate cytology is reflective of a referral-based
population for operation enrolled in surgical clinics.
These clinical data were encoded in a Bayesian Belief Net-
work (BBN) in order to estimate the probability of thyroid
nodule histopathology. As only very few patients in this
cohort had a family history of thyroid cancer or exposure
to radiation we elected not to include these parameters in
the BBN. Figure 1 shows the ROC curve and area under
Table 1: Characteristics of the study population
Patient Characteristics No. %
Gender
Male 46 21.3
Female 170 78.7
Patient age, years mean ± SD = 47.1 ± 15.9
Median (range) 47 (18 – 85)
Disease Characteristics No. %
Serum TSH mean ± SD = 2.6 ± 6.8
Pre-operative thyroid status
Euthyroid 174 80.6
Hyperthyroid 26 12
Hypothyroid 16 7.4
Dominant thyroid nodule size (cm) mean ± SD = 2.8 ± 1.6
Dominant thyroid nodule size
<2 cm 78 35.9
2 – 4 cm 101 46.5
>4 cm 38 17.5
Imaging Characteristics No. %
Thyroid Scintigraphy
Cold 21 58.3
Warm 3 8.3
Hot 12 33.3
Thyroid Ultrasound
Simple cyst 4 1.9
Complex cyst 8 3.7
Mixed 32 14.8
Solid 172 79.6
Thyroid EIS Level of Suspicion
I: Definitely benign 22 10.1
II: Highly unlikely to be malignant 49 22.5BMC Surgery 2009, 9:12 http://www.biomedcentral.com/1471-2482/9/12
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the curve for the model tested a posteriori against the mas-
ter data set of 216 patients for cancer detection, 110 with
malignancy.
The completed BBN was cross-validated using the training
and test sets, and also tested a posteriori against the master
data set to assess predictive power. Table 2 details the
cross-validation results for each train-and-test pair and the
a posteriori testing results. Cross validation of the model
created with Bayesian Network Analysis effectively pre-
dicted malignancy [AUC = 0.88 (95% Confidence Interval
(CI): 0.82–0.94)] in thyroid nodules. The positive and
negative predictive values of the model are 83% (95%CI:
76%–91%) and 79% (95%CI: 72%–86%), respectively.
Sensitivity and specificity of the model are 82% (95%CI:
74%–91%) and 77% (95%CI: 68%–86%), respectively, at
a 50% threshold. In the cross-validation of the BBN
model developed in this study, a 50% probability thresh-
old (most likely case) for calling a case malignant or
benign produced the highest results in this dataset (Table
2 and 3).
The resulting BBN is a directed graph of conditional
dependence between variables. Figure 2 shows the struc-
ture of the BBN developed in this study to predict final
histopathology in 216 patients with thyroid nodules.
What we learn from the structure of the BBN is that four
variables share direct conditional dependence with final
histopathology: fine needle aspiration (FNA) cytology,
maximum nodule size (determined by ultrasound), elec-
trical impedance scan (EIS) and ultrasound (US) charac-
teristics of the nodule. The relative contribution of each of
these four factors was determined by excluding each factor
one at a time in a posteriori analysis against the master data
set of 216 patients. The only factor that significantly
degraded the model, when eliminated from the network,
was thyroid nodule EIS (Table 3). The features directly,
and conditionally dependent with final histopathology
were nodule size, ultrasound and EIS characteristics, and
FNA cytology of the thyroid nodule. Further, the variables
patient age, thyroid nodule size, scintigraphic findings
(hot, warm, cold), and EIS characteristics are also condi-
tionally dependent with one another and through thyroid
nodule size and EIS characteristics inform final histopa-
thology.
With a trained, tested, and cross validated model, the cli-
nician can add evidence to the model given prior knowl-
edge of a specific case through the selection of specific
features and generate case-specific predictions of final his-
topathology. The final pathology diagnosis for a given
patient with thyroid nodule EIS level of suspicion of 2
(highly unlikely to be malignant) has a posterior proba-
bility of cancer of 19%. Adding thyroid nodule ultrasound
finding of 'solid' to the EIS level of suspicion of 2 refines
the case specific posterior estimate of malignancy to 23%,
which is less than the cancer rate in the study population.
Additional data refines the prediction of malignancy even
further; indeterminate FNA cytology of a 'solid' nodule by
US, having EIS level of suspicion of 2 has a posterior prob-
ability of benignity of 85% (15% probability of malig-
nancy). Changing the EIS result from highly unlikely to be
malignant (LOS 2) to level of suspicion of 4 (likely to be
malignant) increases the posterior probability of malig-
nancy from 15% to 65% (Figure 3).
Inference-based individual case-specific estimates of pos-
terior probability from the Bayesian Belief Network can
also be developed by applying the model to new data sets
in either batch inference mode or by tabulating all poten-
tial combinations in an inference table. Table 4 provides
an example of an inference table calculated using the
model developed in this study for all potential combina-
tions of EIS and FNA cytology result, providing the clini-
cian with a simple "look-up table" format which may be
easier to interact with than the model. For example, the
sixth case in Table 4, Definitely Benign EIS (Level of Sus-
picion of 1) and Indeterminate FNA cytology, has a prob-
ability of cancer of 5.7%. However, a patient with an
indeterminate nodule with EIS Level of Suspicion of 4
(likely to be malignant) has a 58.7% probability of thy-
roid malignancy.
Discussion
The primary aim of this study was to develop a Bayesian
Belief Network model based on data collected prospec-
tively in the context of a clinical trial evaluating the feasi-
III: Unlikely to be malignant 21 9.6
IV: Likely to be malignant 64 29.5
V: Highly likely to be malignant 62 28.4
Pathological Characteristics No. %
Fine needle aspiration cytology
Inadequate 6 2.8
Not done 9 4.2
Negative 30 13.9
Positive 62 28.7
Indeterminate 109 50.4
Surgical Histopathology
Benign 106 49.1
Malignant 110 50.9
Table 1: Characteristics of the study population (Continued)BMC Surgery 2009, 9:12 http://www.biomedcentral.com/1471-2482/9/12
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bility of electrical impedance scanning in patients with
thyroid nodules pre-determined to undergo thyroid resec-
tion. Relevant clinical variables were included in the
model in order to develop a model-driven risk assessment
tool, which could support decision making on the basis of
individual patient risk of malignancy. The model created
with Bayesian Network Analysis effectively predicted
malignancy [AUC = 0.88 (95%CI: 0.82–0.94)] in thyroid
nodules. The positive and negative predictive values of the
model are 83% (95%CI: 76%–91%) and 79% (95%CI:
72%–86%), respectively.
The thyroid nodule is a prevalent clinical problem in the
United States, and the majority of nodules are pathologi-
cally benign. The increasingly frequent use of sensitive
diagnostic modalities has contributed to an unprece-
dented rise in the incidence of differentiated thyroid car-
cinoma [18]. The preponderance of identified papillary
thyroid cancer is small sub-clinical, indolent disease;
hence, the challenge to the clinician is differentiating
tumors of favorable biology from those with notoriously
aggressive behavior [18]. Although clinical indicators of
malignancy risk can facilitate therapeutic decision mak-
ing, they are imperfect in directing treatment for those
patients most likely to benefit from thyroidectomy.
Another vexing, more fundamental problem than defin-
ing biology of malignancy, is that of definitively diagnos-
ing the cytologically indeterminate thyroid nodule. This
often necessitates diagnostic operation in a large propor-
tion of patients with so-called "follicular neoplasms", to
benefit possibly the few patients that actually have thyroid
malignancy. Accurately predicting malignancy in any
ROC Curve for cancer prediction in validation against the master data Figure 1
ROC Curve for cancer prediction in validation against the master data. Sensitivity is plotted on the y-axis and 1-spe-
cificity is plotted on the x-axis.BMC Surgery 2009, 9:12 http://www.biomedcentral.com/1471-2482/9/12
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given thyroid nodule remains a daunting clinical chal-
lenge, establishing the need for decision support tools or
predictive models to guide therapeutic decision making.
The present study implemented Bayesian classification on
a prospectively enrolled clinical trial cohort including
clinical, image-based as well as cytological predictors of
malignancy. A clinically relevant prognostic risk assess-
ment tool was constructed and cross validated, which pro-
vides individual patient-specific prediction of malignancy
in thyroid nodules.
Bayesian classification has been applied across the spec-
trum of medicine [19,20] from optimization of pharma-
cotherapy dosing [21,22], predicting cancer screening
[23] and diagnostic test results [24,25], to determining
injury severity [26] and ICU mortality [27], assessing
operative risk [28] and predicting surgical outcomes [29-
32]. More recently, BBN models have been developed to
predict cancer-specific outcomes [33-37]. The findings of
the current study demonstrate that the BBN model pro-
vides an individualized estimate of cancer risk in thyroid
nodules, in three clinically relevant categories of FNA
cytology category: negative, positive, and indeterminate.
The receiver operating characteristic curves can be used to
optimize the model for negative and positive predictive
value in our thyroid cohort. Importantly, a patient in our
broad population with an indeterminate nodule with EIS
Level of Suspicion of 4 or 5 (likely or highly likely to be
malignant) has a 58.7% and 73.6% probability of thyroid
malignancy, respectively, according to the prognostic risk
assessment tool developed and cross-validated herein.
The predictive model developed in this study not only
provides an individualized estimate of risk of malignancy
in patients with a broad spectrum of thyroid nodules, it
also can support integration with clinical systems (elec-
tronic health record) and provide real time estimates of
risk, thereby facilitating clinical decision making and
patient education. The iterative nature of the modeling
methodology permits addition of new data, which can be
used to update, or re-train and validate, dynamically mod-
ify and optimize the model. Model optimization with
new data input over time will be important, as patients
with indeterminate FNA cytology and EIS level of suspi-
cion ranging from 1–3 (Normal to Unlikely to be malig-
nant) in the current model have a clinically meaningful
(~10%) likelihood of malignant histopathology.
There are several limitations inherent in the prognostic
risk assessment tool constructed in this study. Other clin-
ical data such as 18F-FDG Positron Emission Tomography,
Doppler ultrasound, Magnetic Resonance Imaging and
quantitative RT-PCR assays for thyroid-cancer-related
genes of fine needle aspirates, which were not tested in
this clinical trial, may be relevant and could improve the
predictive value of the model.
Ultrasound variables considered in the BBN model devel-
opment included primary thyroid nodule characteristics
(e.g. solid versus cystic) and maximum dimension; how-
ever, other sonographic variables not measured in the
study could have incremental predictive value, including
color Doppler ultrasound-directed qualitative intra-nodu-
lar vascular distribution and microcalcifications, as well as
Table 2: BBN cross-validation results for each train-and-test pair and a posteriori testing results
AUC PV @ 50% Cancer, At 50% Threshold Benign, At 50% Threshold
Benign Cancer Benign Cancer Sensitivity Specificity Sensitivity Specificity
Test 1 71.4% 71.5% 60.0% 66.7% 66.8% 50.0% 60.0% 58.3%
Test 2 93.4% 93.4% 80.0% 81.8% 81.8% 70.0% 90.0% 81.7%
Test 3 89.2% 88.7% 81.3% 85.7% 66.8% 85.7% 92.9% 55.6%
Test 4 89.8% 89.1% 81.8% 66.7% 90.0% 69.2% 77.1% 80.0%
Test 5 92.1% 92.2% 77.8% 91.7% 92.4% 87.5% 87.6% 77.0%
Test 6 99.8% 99.8% 100.0% 100.0% 100.0% 91.6% 100.0% 77.8%
Test 7 76.0% 76.0% 80.0% 80.0% 90.0% 80.0% 80.0% 70.0%
Test 8 90.6% 90.5% 78.6% 85.7% 66.8% 83.3% 100.0% 33.3%
Test 9 89.8% 90.5% 80.0% 81.8% 81.8% 70.0% 90.0% 72.7%
Test 10 88.2% 88.2% 70.0% 91.7% 85.6% 87.5% 87.6% 28.6%
Mean 88.0% 88.0% 78.9% 83.2% 82.2% 77.5% 86.5% 63.5%
Internal 88.6% 89.0% 81.5% 82.6% 81.8% 81.3% 82.4% 81.0%
Table 3: Contribution of first-order predictors (thyroid nodule 
size, US and EIS characteristics, and FNA cytology) to predictive 
power of the Bayesian model
AUC PV @ 50%
Benign Cancer Benign Cancer
No EIS 84.2% 84.6% 75.8% 71.3%
No FNA 88.0% 83.0% 79.5% 82.9%
No US 88.2% 88.4% 80.4% 83.8%
No Nodule Size 92.0% 91.9% 83.5% 81.6%BMC Surgery 2009, 9:12 http://www.biomedcentral.com/1471-2482/9/12
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quantitative analysis of tumor vascularity (tumor vascular
resistive index). Although elimination of thyroid nodule
impedance characteristics from the network significantly
degraded the model in this study, thyroid impedance
remains investigational and warrants further clinical vali-
dation. Further, while the predictive model was cross val-
idated to assess robustness, it remains to be
independently and prospectively validated in a new and
expanded diverse patient population with thyroid nod-
ules. This will be particularly important recognizing
another putative factor limiting the generalizability of our
study results – the selected pre-operative, disease-enriched
population. The increased prevalence of disease biases the
estimates of the positive predictive value (overly optimis-
tic) and negative predictive (overly pessimistic). The ulti-
mate value of the model will rest in its ability to predict
malignancy in a general population of patients with thy-
roid nodules, where the prevalence of malignancy is
decidedly lower. Importantly, we anticipate that the vali-
dated model will be utilized in situations of clinical uncer-
tainty after standard testing (US and FNA) in order to
facilitate clinical decision making with respect to opera-
tive indication.
Recognizing that individual variables, though independ-
ently associated with thyroid cancer, are insufficient in
predicting of risk of malignancy in any given thyroid nod-
ule, other investigators have stressed the importance of
developing multivariate predictive algorithms to deter-
mine cumulative risk of malignancy for this common
clinical problem [38,39]. Raza et al. utilized a multivariate
stepwise regression model to predict malignancy in thy-
roid nodules in a highly selected patient population on
the basis of patient age, calcifications in a sonographically
solid nodule, and FNA cytology [39]. Tuttle, Lamar and
Burch applied multivariate modeling in patients with
indeterminate thyroid nodules to define male gender,
nodule size exceeding 4 cm, and character of the gland by
palpation (dominant nodule in multi-nodular goiter) to
predict risk of thyroid malignancy [38]. Their analysis was
limited to a narrow population of patients with follicular
neoplasia by FNA, and did not include any imaging-based
variables in the predictive model.
Conclusion
Our study is in agreement with these investigations in that
it suggests that a broad statistically validated network
Bayesian Belief Network model: Pathological diagnosis (Overall Pathology Dx) in thyroid nodules (Benign versus Malignant) Figure 2
Bayesian Belief Network model: Pathological diagnosis (Overall Pathology Dx) in thyroid nodules (Benign ver-
sus Malignant). The model structure defines four critical predictors of thyroid nodule histopathology (red circles): fine nee-
dle aspiration (FNA) cytology, maximum nodule size (determined by ultrasound), electrical impedance scan (EIS) and 
ultrasound (US) characteristics of the nodule. Worst EIS is based on LOS: I: Definitely benign; II: Highly unlikely to be malig-
nant; III: Unlikely to be malignant; IV: Likely to be malignant; V: Highly likely to be malignant.BMC Surgery 2009, 9:12 http://www.biomedcentral.com/1471-2482/9/12
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Posterior estimate of surgical pathology outcome derived from prior knowledge of EIS result (EIS level of suspicion of 4 – likely  to be malignant), ultrasound finding of solid thyroid nodule, and indeterminate FNA cytology Figure 3
Posterior estimate of surgical pathology outcome derived from prior knowledge of EIS result (EIS level of sus-
picion of 4 – likely to be malignant), ultrasound finding of solid thyroid nodule, and indeterminate FNA cytol-
ogy. Changing the EIS result from highly unlikely to be malignant (LOS 2) to Level of Suspicion of (likely to be malignant) 
increases the posterior probability of malignancy from 15% to 65% (red ellipses).
Table 4: Inference table calculated using the model developed in this study for all potential combinations of EIS and FNA result, 
selected subset.
EIS Level of Suspicion FNA Cytology Surgical Pathology Diagnosis
Benign Malignant
1-Definitely Benign Inadequate 100.00% 0.00%
2-Highly unlikely to be malignant Inadequate 100.00% 0.00%
3-Unlikely to be malignant Inadequate 100.00% 0.00%
4-Likely to be malignant Inadequate 100.00% 0.00%
5-Highly likely to be malignant Inadequate 100.00% 0.00%
1-Definitely Benign Indeterminate 94.30% 5.70%
2-Highly unlikely to be malignant Indeterminate 87.80% 12.20%
3-Unlikely to be malignant Indeterminate 90.90% 9.10%
4-Likely to be malignant Indeterminate 41.30% 58.70%
5-Highly likely to be malignant Indeterminate 26.40% 73.60%
1-Definitely Benign Negative 98.90% 1.10%
2-Highly unlikely to be malignant Negative 97.60% 2.40%
3-Unlikely to be malignant Negative 98.20% 1.80%
4-Likely to be malignant Negative 79.70% 20.30%
5-Highly likely to be malignant Negative 66.70% 33.30%
1-Definitely Benign Positive 14.90% 85.10%
2-Highly unlikely to be malignant Positive 7.10% 92.90%
3-Unlikely to be malignant Positive 9.50% 90.50%
4-Likely to be malignant Positive 0.70% 99.30%
5-Highly likely to be malignant Positive 0.40% 99.60%BMC Surgery 2009, 9:12 http://www.biomedcentral.com/1471-2482/9/12
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structure of multiple clinical variables has the potential to
provide a universal method to individualize patient care.
The dynamic, quantitative case-specific predictions made
by this type of a predictive model could allow clinical
decision support tools to be adapted to the specific needs
and capabilities of a given medical clinic. This preliminary
yet promising clinical tool clearly warrants further valida-
tion testing in planned prospective trials. If prospective
validation of the model is successful we anticipate the
model to serve as a web-based clinical tool, which can be
accessed by physicians, and utilized by them in order to
evaluate the risk of malignancy in individual patients pre-
senting with thyroid nodule(s).
Abbreviations
BBN: Bayesian Belief Network; EIS: Electrical Impedance
Scanning; ICU: Intensive Care Unit; F-FDG PET: Fluoro-
deoxyglucose Positron Emission Tomography; FNA: Fine
Needle Aspiration; NPV: Negative Predictive Value; PPV:
Positive Predictive Value; ROC: Receiver Operating Char-
acteristics; RT-PCR: Real Time Polymerase Chain Reac-
tion; TSH: Thyrotropin.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
All authors read and approved the final manuscript
AS concived and designed the project, aquired, analysed
and interpreted the data with statistical expertise, drafted
and made critical revisions to the manuscript, obtained
funding and supervied the overall project.
GEP aquired the data, made crittical revisions to the man-
uscript, and supervised the project.
SKL analysed and interpreted the data, made critical revi-
sions to the manuscript and supervised the project.
LRH made crittical revisions to the manuscript.
JE concieved and designed the project, analysed and inter-
preted the data with statistical expertise, drafted and made
critical revisions to the manuscript.
RSH analysed and interpreted the data with statistical
expertise.
DG obtained funding, supervised the project and made
crittical revisions to the manuscript.
EAE made critical revisions to the manuscript.
AN aquired the data, drafted the manuscript, made critical
revisions to the manuscript, obtained funding, and super-
vised the project.
Acknowledgements
The opinions or assertions contained herein are the private views of the 
authors and are not to be construed as official or reflecting the views of the 
Department of the Army, Department of the Navy, or the Department of 
Defense.
This study was support by the Department of Surgery and Department of 
Clinical Investigation, Walter Reed Army Medical Center.
We owe a debt of gratitude to our patients who made this study possible. 
This work was supported through the tireless efforts of our research pro-
gram manager, Mrs. Tiffany Felix.
References
1. Welker MJ, Orlov D: Thyroid nodules.  Am Fam Physician 2003,
67:559-566.
2. Mazzaferri EL: Thyroid cancer in thyroid nodules: finding a
needle in the haystack.  Am J Med 1992, 93:359-62.
3. Baloch ZW, Cibas ES, Clark DP, Layfield LJ, Ljung BM, Pitman MB,
Abati A: The National Cancer Institute Thyroid fine needle
aspiration state of the science conference: a summation.
Cytojournal 2008, 5:6.
4. Are C, Hsu JF, Schoder H, Shah JP, Larson SM, Shaha AR: FDG-PET
detected thyroid incidentalomas: Need for further investiga-
tion?  Ann Surg Oncol 2007, 14:239-247.
5. Sathekge MM, Mageza RB, Muthuphei MN, Modiba CM, Clauss RC:
Evaluation of thyroid nodules with technetium-909m MIBI
and technetium-99m pertechnetate.  Head Neck 2001,
23:305-310.
6. Alexander EK, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas
ES, Marqusee E: Assessment of nondiagnostic ultrasound-
guided fine needle aspirations of thyroid nodules.  J Clin Endo-
crinol Metab 2002, 87(11):4924-7.
7. Baloch ZW, LiVolsi VA: Fine-needle aspiration of thyroid nod-
ules: past, present, and future.  Endocr Pract 2004, 10(3):234-41.
8. Carpi A, Di Coscio G, Iervasi G, Antonelli A, Mechanick J, Sciacchi-
t a n o  S ,  N i c o l i n i  A :  Thyroid fine needle aspiration: how to
improve clinicians' confidence and performance with the
technique.  Cancer Lett 2008, 264(2):163-71.
9. Deveci MS, Deveci G, LiVolsi VA, Baloch ZW: Fine-needle aspira-
tion of follicular lesions of the thyroid. Diagnosis and follow-
Up.  Cytojournal 2006:3-9.
10. Nissan A, Peoples GE, Abu-Wasel B, Adair CF, Prus D, Howard RS,
Lenington SG, Fields SI, Freund HR, Peretz T, Burch HB, Shriver CD,
Stojadinovic A: Prospective trial evaluating electrical imped-
ance scanning of thyroid nodules before thyroidectomy:
Final results.  Ann Surg 2008, 247(5):843-53.
11. Robin H, Eberhardt JS, Armstrong M, Gaertner R, Kam J: Interpret-
ing diagnostic assays by means of statistical modeling, IVD
Technology.  2006, 12(3):55-63.
12. Maskery SM, Zhang YH, Hu H, Shriver C, Hooke J, Liebman M: "Caf-
feine Intake, Race, and Risk of Invasive Breast Cancer Les-
sons Learned from Data Mining a Clinical Database".
Proceedings of the 19th IEEE International Symposium on Computer-Based
Medical Systems, Salt Lake City, UT 22–23 June 2006 2006:714-718.
13. Hofman JM, Wiggins CH: Bayesian approach to network modu-
larity.  Phys Rev Lett 2008, 100(25):258701.
14. Thomas Bayes: "An Essay towards solving a Problem in the
Doctrine of Chances. By the late Rev. Mr. Bayes, F.R.S., com-
municated by Mr. Price, in a letter to John Canton, A.M.,
F.R.S.".  Philosophical Transactions of the Royal Society of London 1763,
53:370-418.
15. Moraleda J, Miller T: Ad+tree: A compact adaptation of
dynamic ad-trees for efficient machine learning on large data
sets.  Proceedings of the 4th International Conference on Intelligent Data
Engineering and Automated Learning 2002.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Surgery 2009, 9:12 http://www.biomedcentral.com/1471-2482/9/12
Page 11 of 11
(page number not for citation purposes)
16. Jensen F: An Introduction to Bayesian Networks.  Springer-Ver-
lag, New York; 1996. 
17. Stojadinovic A, Fields SI, Shriver CD, et al.: Electrical Impedance
Scanning of Thyroid Nodules Prior to Thyroid Surgery: A
Prospective Study.  Annals of Surgical Oncology 2005,
12(2):152-160.
18. Davies L, Welch : Increasing incidence of thyroid cancer in the
United States, 1973–2002.  JAMA 2006, 295(18):2164-7.
19. Howard R, Matheson J, editors: Readings on the Principles and
Applications of Decision Analysis.  Volume 2. Strategic Decisions
Group, Menlo Park, CA; 1996:721-762. 
20. Pearl J: Probabilistic Reasoning in Intelligent Systems: Net-
works of Plausible Inference.  Morgan Kaufmann, San Mateo, CA;
1988. 
21. Wakefield J, Racine-Poon A: An application of Bayesian popula-
tion pharmacokinetic/pharmacodynamic models to dose
recommendation.  Stat Med 1995, 14(9–10):971-86.
22. Rodvold KA, Pryka RD, Kuehl PG, Blum RA, Donahue P: Bayesian
forecasting of serum gentamicin concentrations in intensive
care patients.  Clin Pharmacokinet 1990, 18(5):409-23.
23. Burnside ES, Rubin DL, Fine JP, Shachter RD, Sisney GA, Leung WK:
Bayesian network to predict breast cancer risk of mammo-
graphic microcalcifications and reduce number of benign
biopsy results: initial experience.  Radiology 2006,
240(3):666-73.
24. Christiansen CL, Wang F, Barton MB, et al.: Predicting the cumu-
lative risk of false-positive mammograms.  J Natl Cancer Inst
2000, 92(20):1657-66.
25. Edwards FH, Schaefer PS, Cohen AJ, et al.: Use of artificial intelli-
gence for the preoperative diagnosis of pulmonary lesions.
Ann Thorac Surg 1989, 48(4):556-9.
26. Burd RS, Ouyang M, Madigan D: Bayesian logistic injury severity
score: a method for predicting mortality using international
classification of disease-9 codes.  Acad Emerg Med 2008,
15(5):466-75.
27. Ho KM, Knuiman M: Bayesian approach to predict hospital
mortality of intensive care readmissions during the same
hospitalisation.  Anaesth Intensive Care 2008, 36(1):38-45.
28. Fazio VW, Tekkis PP, Remzi F, Lavery IC: Assessment of operative
risk in colorectal cancer surgery: the Cleveland Clinic Foun-
dation colorectal cancer model.  Dis Colon Rectum 2004,
47(12):2015-24.
29. Edwards FH, Peterson RF, Bridges C, Ceithaml EL: Use of a Baye-
sian statistical model for risk assessment in coronary artery
surgery. Updated in 1995.  Ann Thorac Surg 1988, 59(6):1611-2.
30. Biagioli B, Scolletta S, Cevenini G, Barbini E, Giomarelli P, Barbini P:
A multivariate Bayesian model for assessing morbidity after
coronary artery surgery.  Crit Care 2006, 10(3):R94.
31. Lenihan CR, O'Kelly P, Mohan P, et al.: MDRD-estimated GFR at
one year post-renal transplant is a predictor of long-term
graft function.  Ren Fail 2008, 30(4):345-52.
32. Hoot N, Aronsky D: Using Bayesian networks to predict sur-
vival of liver transplant patients.  AMIA Annu Symp Proc
2005:345-9.
33. Okamoto T, Yamazaki K, Kanbe M, et al.: Probability of axillary
lymph node metastasis when sentinel lymph node biopsy is
negative in women with clinically node negative breast can-
cer: a Bayesian approach.  Breast Cancer 2005, 12(3):203-10.
34. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy
S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR: Patterns
of gene expression that characterize long-term survival in
advanced stage serous ovarian cancers.  Clin Cancer Res 2005,
11(10):3686-96.
35. Berry DA, Inoue L, Shen Y, et al.: Modeling the impact of treat-
ment and screening on U.S. breast cancer mortality: a Baye-
sian approach.  J Natl Cancer Inst Monogr 2006, 36:30-6.
36. Erkanli A, Taylor DD, Dean D, et al.: Application of Bayesian
modeling of autologous antibody responses against ovarian
tumor-associated antigens to cancer detection.  Cancer Res
2006, 66(3):1792-8.
37. Damato B, Eleuteri A, Fisher A, Coupland SE, Taktak AF: Artificial
Neural Networks Estimating Survival Probability after
Treatment of Choroidal Melanoma.  Ophthalmology 2008,
115(9):1598-1607.
38. Tuttle RM, Lemar H, Burch HB: Clinical features associated with
an increased risk of thyroid malignancy in patients with fol-
licular neoplasia by fine-needle aspiration.  Thyroid 1998,
8(5):377-83.
39. Raza SN, Shah MD, Palme CE, et al.: Risk factors for well-differen-
tiated thyroid carcinoma in patients with thyroid nodular
disease.  Otolaryngol Head Neck Surg 2008, 139(1):21-6.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2482/9/12/prepub